Drug treatment in type 2 diabetes (part 2)

Drug treatment in type 2 diabetes (part 2)

Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helpi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:La Presse médicale (1983) 2007-03, Vol.36 (3 Pt 2), p.467-474
Hauptverfasser: Tielmans, Amélie, Virally, Marie, Coupaye, Muriel, Laloi-Michelin, Marie, Méas, Taly, Guillausseau, Pierre-Jean
Format: Artikel
Sprache:fre
Schlagworte:
Anti-Obesity Agents - therapeutic use
Diabetes Mellitus, Type 2 - drug therapy
Glycoside Hydrolase Inhibitors
Humans
Insulin - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 474
container_issue 3 Pt 2
container_start_page 467
container_title La Presse médicale (1983)
container_volume 36
creator Tielmans, Amélie
Virally, Marie
Coupaye, Muriel
Laloi-Michelin, Marie
Méas, Taly
Guillausseau, Pierre-Jean
description Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helping patients lose weight. Orlistat inhibits hydrolysis of dietary triglycerides. Sibutramine, a noradrenaline and serotonin reuptake inhibitor, reinforces feelings of satiety and increases energy expenditure. After approximately 10 years, insulin therapy is usually required together with oral antidiabetic agents (except glitazones) or alone if HbA(1c) (glycosylated hemoglobin) is>6.5%. New guidelines for management of type 2 diabetes were published in 2006.
doi_str_mv 10.1016/j.lpm.2006.11.015
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70239645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70239645</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-3a4929f3e4314c002688cb628cbb72da20bba1caa8c36ed722dcbdf97bd311ee3</originalsourceid><addsrcrecordid>eNo1j71OwzAYRT2AaCk8AAvyhAApwZ9_4xGVX6kSC8yRHX9BqZLWxM7QtycSZbl3OTpXl5ArYCUw0A_bso9DyRnTJUDJQJ2QJTNKFdJWfEHOU9oyxkEae0YWYITQlVJLcv80Tt80j-jygLtMux3Nh4iU09A5jxkTvY1uzJTfXZDT1vUJL4-9Il8vz5_rt2Lz8fq-ftwUEYTNhXDSctsKlAJkM2_qqmq85nN4w4PjzHsHjXNVIzQGw3lofGit8UEAIIoVufnzxnH_M2HK9dClBvve7XA_pdowLqyWagavj-DkBwx1HLvBjYf6_534BQbGTqc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70239645</pqid></control><display><type>article</type><title>Drug treatment in type 2 diabetes (part 2)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Tielmans, Amélie ; Virally, Marie ; Coupaye, Muriel ; Laloi-Michelin, Marie ; Méas, Taly ; Guillausseau, Pierre-Jean</creator><creatorcontrib>Tielmans, Amélie ; Virally, Marie ; Coupaye, Muriel ; Laloi-Michelin, Marie ; Méas, Taly ; Guillausseau, Pierre-Jean</creatorcontrib><description>Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helping patients lose weight. Orlistat inhibits hydrolysis of dietary triglycerides. Sibutramine, a noradrenaline and serotonin reuptake inhibitor, reinforces feelings of satiety and increases energy expenditure. After approximately 10 years, insulin therapy is usually required together with oral antidiabetic agents (except glitazones) or alone if HbA(1c) (glycosylated hemoglobin) is&gt;6.5%. New guidelines for management of type 2 diabetes were published in 2006.</description><identifier>ISSN: 0755-4982</identifier><identifier>DOI: 10.1016/j.lpm.2006.11.015</identifier><identifier>PMID: 17336855</identifier><language>fre</language><publisher>France</publisher><subject>Anti-Obesity Agents - therapeutic use ; Diabetes Mellitus, Type 2 - drug therapy ; Glycoside Hydrolase Inhibitors ; Humans ; Insulin - therapeutic use</subject><ispartof>La Presse médicale (1983), 2007-03, Vol.36 (3 Pt 2), p.467-474</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17336855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tielmans, Amélie</creatorcontrib><creatorcontrib>Virally, Marie</creatorcontrib><creatorcontrib>Coupaye, Muriel</creatorcontrib><creatorcontrib>Laloi-Michelin, Marie</creatorcontrib><creatorcontrib>Méas, Taly</creatorcontrib><creatorcontrib>Guillausseau, Pierre-Jean</creatorcontrib><title>Drug treatment in type 2 diabetes (part 2)</title><title>La Presse médicale (1983)</title><addtitle>Presse Med</addtitle><description>Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helping patients lose weight. Orlistat inhibits hydrolysis of dietary triglycerides. Sibutramine, a noradrenaline and serotonin reuptake inhibitor, reinforces feelings of satiety and increases energy expenditure. After approximately 10 years, insulin therapy is usually required together with oral antidiabetic agents (except glitazones) or alone if HbA(1c) (glycosylated hemoglobin) is&gt;6.5%. New guidelines for management of type 2 diabetes were published in 2006.</description><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Glycoside Hydrolase Inhibitors</subject><subject>Humans</subject><subject>Insulin - therapeutic use</subject><issn>0755-4982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j71OwzAYRT2AaCk8AAvyhAApwZ9_4xGVX6kSC8yRHX9BqZLWxM7QtycSZbl3OTpXl5ArYCUw0A_bso9DyRnTJUDJQJ2QJTNKFdJWfEHOU9oyxkEae0YWYITQlVJLcv80Tt80j-jygLtMux3Nh4iU09A5jxkTvY1uzJTfXZDT1vUJL4-9Il8vz5_rt2Lz8fq-ftwUEYTNhXDSctsKlAJkM2_qqmq85nN4w4PjzHsHjXNVIzQGw3lofGit8UEAIIoVufnzxnH_M2HK9dClBvve7XA_pdowLqyWagavj-DkBwx1HLvBjYf6_534BQbGTqc</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Tielmans, Amélie</creator><creator>Virally, Marie</creator><creator>Coupaye, Muriel</creator><creator>Laloi-Michelin, Marie</creator><creator>Méas, Taly</creator><creator>Guillausseau, Pierre-Jean</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200703</creationdate><title>Drug treatment in type 2 diabetes (part 2)</title><author>Tielmans, Amélie ; Virally, Marie ; Coupaye, Muriel ; Laloi-Michelin, Marie ; Méas, Taly ; Guillausseau, Pierre-Jean</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-3a4929f3e4314c002688cb628cbb72da20bba1caa8c36ed722dcbdf97bd311ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2007</creationdate><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Glycoside Hydrolase Inhibitors</topic><topic>Humans</topic><topic>Insulin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tielmans, Amélie</creatorcontrib><creatorcontrib>Virally, Marie</creatorcontrib><creatorcontrib>Coupaye, Muriel</creatorcontrib><creatorcontrib>Laloi-Michelin, Marie</creatorcontrib><creatorcontrib>Méas, Taly</creatorcontrib><creatorcontrib>Guillausseau, Pierre-Jean</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La Presse médicale (1983)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tielmans, Amélie</au><au>Virally, Marie</au><au>Coupaye, Muriel</au><au>Laloi-Michelin, Marie</au><au>Méas, Taly</au><au>Guillausseau, Pierre-Jean</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug treatment in type 2 diabetes (part 2)</atitle><jtitle>La Presse médicale (1983)</jtitle><addtitle>Presse Med</addtitle><date>2007-03</date><risdate>2007</risdate><volume>36</volume><issue>3 Pt 2</issue><spage>467</spage><epage>474</epage><pages>467-474</pages><issn>0755-4982</issn><abstract>Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helping patients lose weight. Orlistat inhibits hydrolysis of dietary triglycerides. Sibutramine, a noradrenaline and serotonin reuptake inhibitor, reinforces feelings of satiety and increases energy expenditure. After approximately 10 years, insulin therapy is usually required together with oral antidiabetic agents (except glitazones) or alone if HbA(1c) (glycosylated hemoglobin) is&gt;6.5%. New guidelines for management of type 2 diabetes were published in 2006.</abstract><cop>France</cop><pmid>17336855</pmid><doi>10.1016/j.lpm.2006.11.015</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0755-4982
ispartof La Presse médicale (1983), 2007-03, Vol.36 (3 Pt 2), p.467-474
issn 0755-4982
language fre
recordid cdi_proquest_miscellaneous_70239645
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Anti-Obesity Agents - therapeutic use
Diabetes Mellitus, Type 2 - drug therapy
Glycoside Hydrolase Inhibitors
Humans
Insulin - therapeutic use
title Drug treatment in type 2 diabetes (part 2)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T18%3A20%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20treatment%20in%20type%202%20diabetes%20(part%202)&rft.jtitle=La%20Presse%20m%C3%A9dicale%20(1983)&rft.au=Tielmans,%20Am%C3%A9lie&rft.date=2007-03&rft.volume=36&rft.issue=3%20Pt%202&rft.spage=467&rft.epage=474&rft.pages=467-474&rft.issn=0755-4982&rft_id=info:doi/10.1016/j.lpm.2006.11.015&rft_dat=%3Cproquest_pubme%3E70239645%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70239645&rft_id=info:pmid/17336855&rfr_iscdi=true